**Rhesus TNFRSF17 / BCMA (CD269) protein (Fc & AVI Tag), Biotinylated**

**Catalog Number:** 90103-C35H-B

---

### General Information

**Gene Name Synonym:**

TNFRSF17

**Protein Construction:**

A DNA sequence encoding the rhesus TNFRSF17 (XP_001106892.1) (Met1-Ala53) was expressed with a c-terminal AVI tagged Fc region of human IgG1 tag at the C-terminus. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed.

**Source:** Rhesus

**Expression Host:** HEK293 Cells

---

### QC Testing

**Biotin/Protein Ratio:**

0.7-1 as determined by the HABA assay.

**Purity:** 

> 95 % as determined by SDS-PAGE.

**Endotoxin:**

< 1.0 EU per μg protein as determined by the LAL method.

**Stability:**

Samples are stable for up to twelve months from date of receipt at -70 °C

**Predicted N terminal:**

Met

**Molecular Mass:**

The recombinant TNFRSF17 consists of 306 amino acids and predicts a molecular mass of 34.5 kDa.

**Formulation:**

Lyophilized from sterile PBS, pH 7.4.

Normally 5 % - 8 % trehalose, manitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

### Usage Guide

**Storage:**

Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

**Avoid repeated freeze-thaw cycles.**

**Reconstitution:**

Detailed reconstitution instructions are sent along with the products.

---

**SDS-PAGE:**

![SDS-PAGE Image]

**Protein Description**

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

**References**